Marcilly, France

Gérard Puchault


Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1998-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Gérard Puchault: Innovator in Antimicrobial Agents

Introduction

Gérard Puchault is a notable inventor based in Marcilly, France. He has made significant contributions to the field of antimicrobial agents, holding a total of 4 patents. His work focuses on the development of streptogramin derivatives, which are crucial in combating bacterial infections.

Latest Patents

Puchault's latest patents include innovative formulations of Group B streptogramin derivatives. These derivatives are characterized by a general formula (I), where specific groups are defined in the patent description. The preparation methods and compositions containing these derivatives are particularly useful as antimicrobial agents. They can be optionally combined with at least one Group A streptogramin derivative, enhancing their effectiveness in medical applications.

Career Highlights

Gérard Puchault has built a distinguished career at Aventis Pharma S.A., where he has been instrumental in advancing pharmaceutical research. His expertise in the field of antimicrobial agents has positioned him as a key player in the industry. His contributions have not only led to the development of new drugs but have also improved existing treatment protocols.

Collaborations

Throughout his career, Puchault has collaborated with esteemed colleagues such as Pascal Desmazeau and Gilles Doerflinger. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Gérard Puchault's work in the development of streptogramin derivatives showcases his commitment to advancing medical science. His patents reflect a deep understanding of antimicrobial agents and their applications. Through his career at Aventis Pharma S.A., he continues to make a significant impact in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…